{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:17:30Z","timestamp":1775110650294,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to investigate and compare the post-marketing safety profiles of three widely used enzyme replacement therapies (ERTs) for Gaucher disease\u2014imiglucerase, velaglucerase alfa, and taliglucerase alfa. ERT involves the intravenous administration of recombinant lysosomal enzymes to compensate for the deficiency of \u03b2-glucocerebrosidase, thereby reducing the accumulation of glucocerebroside in macrophages and alleviating systemic complications. While ERT has transformed disease management, concerns about long-term adverse events persist. This analysis seeks to identify and characterize distinct safety signals associated with each agent, with a focus on disproportionality analysis rather than establishing causality. The findings aim to inform more vigilant, agent-specific clinical monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse event reports were extracted from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analyses were performed using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Patient demographics, significant Preferred Terms (PTs\u2014i.e., specific, medically-encoded adverse event descriptions), and time to onset were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4,256 AE reports were analyzed. Our signal detection analysis identified a distinct set of statistically significant safety signals for each drug after controlling for background reporting rates. These included 37 significantly associated PTs for imiglucerase, 34 for velaglucerase alfa, and 25 for taliglucerase alfa. The safety profiles differed notably; a significant proportion of the signals for imiglucerase and velaglucerase alfa were infection-related (e.g., respiratory tract infections), whereas such signals were far less prominent for taliglucerase alfa. Unique signals included ear infection for imiglucerase, zinc deficiency for velaglucerase alfa, and hepatic fibrosis for taliglucerase alfa. The median time to onset of these signals differed significantly between agents (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-term monitoring is essential during ERT for GD. Clinical vigilance should be heightened for infection-related complications with imiglucerase and velaglucerase alfa, while agent-specific risks like hepatic fibrosis with taliglucerase alfa warrant attention. The observed female predominance in AE reports merits further investigation. These findings are hypothesis-generating; future studies are needed to determine causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1726282","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:18Z","timestamp":1775107398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events signals of enzyme replacement drugs of Gaucher disease: insights from FAERS database analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiaxun","family":"Jiao","sequence":"first","affiliation":[{"name":"Department of Spinal Surgery, The People's Hospital of Hengshui","place":["Hengshui, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongyun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Hengshui","place":["Hengshui, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingna","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Hengshui","place":["Hengshui, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University","place":["Taizhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Hengshui","place":["Hengshui, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3760\/cma.j.cn112140-20210611-00494","article-title":"Expert consensus on diagnosis and treatment of pediatric Gaucher disease (2021)","volume":"59","year":"2021","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.braindev.2022.09.006","article-title":"Perinatal lethal Gaucher disease: a case report and review of literature","volume":"45","author":"Chida","year":"2023","journal-title":"Brain Dev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"175023","DOI":"10.1016\/j.ejphar.2022.175023","article-title":"Update of treatment for Gaucher disease","volume":"926","author":"Kong","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/joim.20114","article-title":"Gaucher disease, state of the art and perspectives","volume":"298","author":"Camou","year":"2025","journal-title":"J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/diagnostics14242840","article-title":"An overview of Gaucher disease","volume":"14","author":"M\u00e9ndez-Cobi\u00e1n","year":"2024","journal-title":"Diagnostics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1007\/s00277-024-05918-2","article-title":"Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease","volume":"103","author":"Motta","year":"2024","journal-title":"Ann Hematol"},{"key":"ref7","first-page":"82","article-title":"Management of Gaucher disease: enzyme replacement therapy","volume":"12","author":"Zimran","year":"2014","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nrd3311","article-title":"Velaglucerase alfa","volume":"9","author":"Aerts","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2146\/news120041","article-title":"Taliglucerase alfa approved for Gaucher disease","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1623921","DOI":"10.3389\/fphar.2025.1623921","article-title":"Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)","volume":"16","author":"Lin","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2446429","article-title":"A real-world pharmacovigilance analysis for agalsidase beta: findings from the FDA adverse event reporting database","volume":"33","author":"Xie","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40259-022-00564-4","article-title":"Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase(\u00ae))","volume":"37","author":"Dernoncourt","year":"2023","journal-title":"BioDrugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","article-title":"Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database","volume":"111","author":"Liu","year":"2025","journal-title":"Int J Surg"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","article-title":"Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database","volume":"25","author":"Liu","year":"2024","journal-title":"J Headache Pain"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1586361","DOI":"10.3389\/fimmu.2025.1586361","article-title":"Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","article-title":"Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance","volume":"39","author":"Heo","year":"2020","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7699","DOI":"10.3390\/ijms22147699","article-title":"Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations","volume":"22","author":"Dinur","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40264-021-01125-4","article-title":"Use of identical INN \u201cImiglucerase\u201d for different drug products: impact analysis of adverse events in a proprietary global safety database","volume":"45","author":"Tsang","year":"2022","journal-title":"Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-024-07789-z","article-title":"Immune system adaptation during gender-affirming testosterone treatment","volume":"633","author":"Lakshmikanth","year":"2024","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/biomedicines12030579","article-title":"Women with Gaucher disease","volume":"12","author":"Meijon-Ortigueira","year":"2024","journal-title":"Biomedicine"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1726282\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:20Z","timestamp":1775107400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1726282\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1726282"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1726282","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1726282"}}